Masoprocol

CHEMBL313972 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
302.4 g/mol
LogP
4.3
Phase
4

This compound derived from the creosote bush plant was approved as a topical treatment for a precancerous skin condition called actinic keratosis, working by inhibiting an enzyme involved in the production of inflammatory compounds that promote abnormal cell growth. It was withdrawn due to a high rate of allergic contact dermatitis.

Molecular Weight

302.4000 g/mol

LogP

4.30

TPSA

80.90 Ų

Lipinski RO5

Pass

Therapeutic Areas

Mechanism of Action

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[C@H](Cc1ccc(O)c(O)c1)[C@@H](C)Cc1ccc(O)c(O)c1

InChI

InChI=1S/C18H22O4/c1-11(7-13-3-5-15(19)17(21)9-13)12(2)8-14-4-6-16(20)18(22)10-14/h3-6,9-12,19-22H,7-8H2,1-2H3/t11-,12+

Molecular Formula

C18H22O4

HBD / HBA

4 / 4

Rotatable Bonds

5

Heavy Atoms

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

This compound derived from the creosote bush plant was approved as a topical treatment for a precancerous skin condition called actinic keratosis, working by inhibiting an enzyme involved in the production of inflammatory compounds that promote abnormal cell growth. It was withdrawn due to a high rate of allergic contact dermatitis.

Applied directly to the skin or mucous membranes, where it exerts its therapeutic effect locally at the site of application with minimal systemic absorption.

Yes, Masoprocol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL313972. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 71398. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.